



iTeos Therapeutics Announces New Scientific Advisory Board Members

September 10, 2019

Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman, William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos' pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer.

The full SAB comprises:

- **Gordon Freeman, Ph.D.**, Researcher at Boston's Dana-Farber Cancer Institute, who will become Chairman of the SAB
- **William C. Hahn, M.D., Ph.D.**, Chief Research Strategy Officer at Boston's Dana-Farber Cancer Institute
- **Ben Z. Stanger, M.D.**, Professor in Cancer Research at the University of Pennsylvania's Perelman School of Medicine
- **Matthew G. Vander Heiden, Ph.D.**, Associate Director at the Massachusetts Institute of Technology's (MIT) Koch Institute for Integrative Cancer Research
- **Benoit Van den Eynde M.D., Ph.D.**, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB
- **Pierre Coulie, M.D., Ph.D.**, Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain
- **Scott Chappel, Ph.D.**, Chief Scientific Officer at iTeos Therapeutics

Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: "By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable.

"While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours."

Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: "I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos' pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A_{2A} pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development."

Additional background on all SAB members can be found on the iTeos [website](#).

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteosterapeutics.com

Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US)

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

Sarah McCabe and Carl Mauch

Stern Investor Relations, Inc.

+ 1 212 362 1200

iTeos@sternir.com